Great pullback - now the fun begins Long

CRISPR Therapeutics AGNASDAQ

Description

⋅ Jan 28, 2021 2:42 PM

CRSP is leader in Genomics and this recent pullback is a perfect buying opportunity for new entrants. If our Elliott wave impulse thesis plays out, the next target could be $290. LONG

Comments

johnpfeifer4

⋅ Feb 10, 2021 9:15 PM

Nice chart, looking good so far!